What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Asthma
- Disease
His primary areas of investigation include Asthma, Internal medicine, Immunology, Sputum and Eosinophil.
The study incorporates disciplines such as Eosinophilia, Respiratory disease and Randomized controlled trial in addition to Asthma.
His Internal medicine research integrates issues from Gastroenterology and Placebo.
The various areas that Ian D. Pavord examines in his Immunology study include Bronchoalveolar lavage and Eosinophilic.
His Sputum study integrates concerns from other disciplines, such as Prostaglandin and Surgery.
The concepts of his Eosinophil study are interwoven with issues in Inhalation and Anti-asthmatic Agent.
His most cited work include:
- Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. (1443 citations)
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma (1404 citations)
- Cluster analysis and clinical asthma phenotypes. (1360 citations)
What are the main themes of his work throughout his whole career to date?
Asthma, Internal medicine, Immunology, Sputum and COPD are his primary areas of study.
His studies deal with areas such as Randomized controlled trial, Airway and Intensive care medicine as well as Asthma.
The Internal medicine study combines topics in areas such as Gastroenterology and Placebo.
The study of Immunology is intertwined with the study of Eosinophilic in a number of ways.
His Sputum study combines topics in areas such as Respiratory disease and Spirometry.
Ian D. Pavord has included themes like Biomarker and Pulmonary disease in his COPD study.
He most often published in these fields:
- Asthma (47.23%)
- Internal medicine (38.92%)
- Immunology (27.95%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (38.92%)
- Asthma (47.23%)
- Dupilumab (4.94%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Asthma, Dupilumab, In patient and Intensive care medicine.
The study incorporates disciplines such as Gastroenterology and Placebo in addition to Internal medicine.
Ian D. Pavord interconnects Post-hoc analysis and Eosinophil in the investigation of issues within Placebo.
His biological study focuses on Exhaled nitric oxide.
His Intensive care medicine research includes elements of Inhaled corticosteroids, Precision medicine and MEDLINE.
In his work, Eosinophilic and Immunology is strongly intertwined with Sputum, which is a subfield of Mepolizumab.
Between 2018 and 2021, his most popular works were:
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (472 citations)
- Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma (123 citations)
- Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. (87 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Asthma
- Disease
Ian D. Pavord mostly deals with Asthma, Internal medicine, Intensive care medicine, MEDLINE and Exhaled nitric oxide.
His study in Asthma focuses on Asthma Control Questionnaire in particular.
His study connects Placebo and Internal medicine.
His biological study spans a wide range of topics, including Precision medicine, Inhalation, Guideline, Inhaled corticosteroids and Asthma control.
His Exhaled nitric oxide study combines topics from a wide range of disciplines, such as Gastroenterology and Inhaler.
Within one scientific family, Ian D. Pavord focuses on topics pertaining to Immunology under COPD, and may sometimes address concerns connected to Fibrocyte and Prostaglandin D2.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
